Purpose: The purpose of this study was to evaluate odds of major bleeding, thrombosis, and ischemic stroke between different enoxaparin dosage strategies in patients weighing ≥120 kg. Methods: Patients weighing ≥120 kg who received therapeutic anticoagulation with enoxaparin for more than 24 hours were selected for retrospective review. Patients without a baseline weight, serum creatinine, a history of heparin-induced thrombocytopenia, or currently pregnant patients were excluded from the study. Patients with a creatinine clearance (CrCL) <30 mL/min were analyzed separately. The incidence of major bleeding was compared between patients receiving <90% and those receiving ≥90% of the Food and Drug Administration (FDA)-approved dose of enoxaparin, as well as between patients weighing ≥150 kg and those weighing <150 kg. Secondary outcomes included incidence of venous thromboembolism (VTE) and ischemic stroke. Results: A total of 462 patients were included in the primary analysis and 25 patients in the subgroup analysis. No difference in major bleeding was observed between different dosage regimens (P = .12) or weight groups (P = .36). No difference was observed in rates of VTE or ischemic stroke between different dosage regimens (P = .52 and P = .60, respectively) or weight groups (P = .39 and P = .48, respectively). Similar results were observed in the low-CrCL analysis. Results were not altered when patients were propensity matched on baseline characteristics. Conclusion: Reducing the dose of enoxaparin did not reduce the odds of major bleeding or increase the odds of ischemic stroke or VTE.
Purpose: The purpose of this study was to evaluate odds of major bleeding, thrombosis, and ischemic stroke between different enoxaparin dosage strategies in patients weighing ≥120 kg. Methods:Patients weighing ≥120 kg who received therapeutic anticoagulation with enoxaparin for more than 24 hours were selected for retrospective review. Patients without a baseline weight, serum creatinine, a history of heparin-induced thrombocytopenia, or currently pregnant patients were excluded from the study. Patients with a creatinine clearance (CrCL) <30 mL/min were analyzed separately. The incidence of major bleeding was compared between patients receiving <90% and those receiving ≥90% of the Food and Drug Administration (FDA)-approved dose of enoxaparin, as well as between patients weighing ≥150 kg and those weighing <150 kg. Secondary outcomes included incidence of venous thromboembolism (VTE) and ischemic stroke. Results: A total of 462 patients were included in the primary analysis and 25 patients in the subgroup analysis. No difference in major bleeding was observed between different dosage regimens (P = .12) or weight groups (P = .36). No difference was observed in rates of VTE or ischemic stroke between different dosage regimens (P = .52 and P = .60, respectively) or weight groups (P = .39 and P = .48, respectively). Similar results were observed in the low-CrCL analysis. Results were not altered when patients were propensity matched on baseline characteristics. Conclusion: Reducing the dose of enoxaparin did not reduce the odds of major bleeding or increase the odds of ischemic stroke or VTE.
Entities:
Keywords:
anticoagulants; medication safety; monitoring drug therapy; physician prescribing
Authors: Roxana Mehran; Sunil V Rao; Deepak L Bhatt; C Michael Gibson; Adriano Caixeta; John Eikelboom; Sanjay Kaul; Stephen D Wiviott; Venu Menon; Eugenia Nikolsky; Victor Serebruany; Marco Valgimigli; Pascal Vranckx; David Taggart; Joseph F Sabik; Donald E Cutlip; Mitchell W Krucoff; E Magnus Ohman; Philippe Gabriel Steg; Harvey White Journal: Circulation Date: 2011-06-14 Impact factor: 29.690
Authors: R Barba; J Marco; H Martín-Alvarez; P Rondon; C Fernández-Capitan; F Garcia-Bragado; M Monreal Journal: J Thromb Haemost Date: 2005-05 Impact factor: 5.824
Authors: Nathaniel R Thompson-Moore; Matthew A Wanat; David R Putney; Phuong H Nguyen Liebl; Wayne L Chandler; James E Muntz Journal: Clin Appl Thromb Hemost Date: 2015-01-19 Impact factor: 2.389
Authors: Jeffrey T Lalama; Megan E Feeney; Jeremy W Vandiver; K Diane Beavers; Leah N Walter; Jacqueline R McClintic Journal: J Thromb Thrombolysis Date: 2015-05 Impact factor: 2.300
Authors: Jacqueline G Gerhart; Fernando O Carreño; Matthew Shane Loop; Craig R Lee; Andrea N Edginton; Jaydeep Sinha; Karan R Kumar; Carl M Kirkpatrick; Christoph P Hornik; Daniel Gonzalez Journal: Clin Pharmacol Ther Date: 2022-05-18 Impact factor: 6.903